AstraZeneca Slapped with Antitrust Lawsuit Over Toprol

Law360, New York (February 21, 2006, 12:00 AM EST) -- Charged once again with violating U.S. competition law, pharmaceutical giant AstraZeneca stands accused of illegally trying to prevent generic versions of its blockbuster heart drug Toprol-XL from entering the marketplace in a lawsuit filed recently by a pension fund.

The Plumbers and Pipefitter Local 572 Pension Fund filed the action last Wednesday in U.S. District Court for the District of Delaware, just as Astra Zeneca announced plans to appeal a January court ruling that scuttled its patents for Toprol-XL and threatened its pipeline of branded drugs....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.